Dr. Lal PathLabs reported Q1 FY27 results on July 24, 2026: revenue grew 19.1% YoY to ₹798 crore, while EBITDA surged 28.7% to ₹247 crore and net profit climbed ~21% to ₹170 crore — with EBITDA margin expanding 230 basis points to 31%. The stock jumped nearly 8% on the day.
Revenue grew 19%. EBITDA grew 29%. Profit grew 21%. Three different numbers, all from the same quarter. Which one tells you the most about the business? I'd argue it's the middle one — and here's how a CFO reads it.
EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) strips out financing choices, tax jurisdictions and accounting for long-lived assets. What's left is the operating engine — how efficiently the business converts revenue into cash-like profit. When EBITDA grows faster than revenue, that gap is the fingerprint of operating leverage: fixed costs (lab equipment, hub infrastructure, tech platforms) are largely the same whether you run 10 million tests or 12 million. More volume means more rupees drop to operating profit without a proportional cost increase.
Dr. Lal PathLabs' EBITDA margin moved from 28.7% to 31% — a 230 basis-point jump. In a diagnostics business, that's meaningful. Labs have high fixed overhead (equipment, certified staff, cold-chain logistics). Once those are covered, incremental tests are highly profitable.
A CFO would ask: is this margin expansion structural or seasonal? The CEO called it the fastest revenue growth in four years, driven by patient volume, better test-mix and government health-scheme pricing. That combination — volume + mix + price — is the cleanest kind of EBITDA expansion.
Watch what a CFO watches: not just 'profit went up' but 'did margin expand, and why?' That 'why' tells you whether growth is compounding or just lucky.
📚 Learn the concept: EBITDA & EBIT
▶ Play the 90-second CFO game All daily posts